Lymphocytic profiling in thyroid cancer provides clues for failure of tumor immunity

Imam, Shahnawaz; Paparodis, Rodis; Sharma, Deepak; Jaume, Juan Carlos

doi:10.1530/erc-13-0436

Cited by 43 publications

(53 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Cancer immunoediting has been reported for other human cancers already (26). Further studies are needed to assess the types of immunity involved in the different forms of HT, and their effect on thyroid cancer development or vice versa (27).…”

Section: Discussionmentioning

confidence: 99%

Hashimoto's Thyroiditis Pathology and Risk for Thyroid Cancer

Paparodis

Imam

Todorova‐Koteva

et al. 2014

Thyroid

Self Cite

View full text Add to dashboard Cite

Background: Hashimoto's thyroiditis (HT) has been found to coexist with differentiated thyroid cancer (DTC) in surgical specimens, but an association between the two conditions has been discounted by the medical literature. Therefore, we performed this study to determine any potential relationship between HT and the risk of developing DTC. Methods: We collected data for thyrotropin (TSH), thyroxine (T 4 ), thyroid peroxidase antibody (TPO-Ab) titers, surgical pathology, and weight-based levothyroxine (LT 4 ) replacement dose for patients who were referred for thyroid surgery. Patients with HT at final pathology were studied further. To estimate thyroid function, patients with preoperative hypothyroid HT (Hypo-HT) were divided into three equal groups based on their LT 4 replacement: LT 4 -Low (<0.90 lg/kg), LT 4 -Mid (0.90-1.43 lg/kg), and LT 4 -High (>1.43 lg/kg). A group of preoperatively euthyroid (Euth-HT) patients but with HT by pathology was also studied. All subjects were also grouped based on their TPO-Ab titer in TPO-high (titer >1:1000) or TPO-low/negative (titer <1:1000 or undetectable) groups. The relationship of HT and DTC was studied extensively. Results: Of 2811 subjects, 582 had HT on surgical pathology, 365 of whom were Euth-HT preoperatively. DTC was present in 47.9% of the Euth-HT, in 59.7% of LT 4 -Low, 29.8% of LT 4 -Mid, and 27.9% of LT 4 -High groups. The relative risk (RR) for DTC was significantly elevated for the Euth-HT and LT 4 -Low groups ( p < 0.001), but not for the LT 4 -Mid or LT 4 -High replacement dose groups. TPO-low/negative status conferred an increased RR in the Euth-HT and LT 4 -Low replacement dose groups ( p < 0.001 both), while TPO-high status decreased it in Euth-HT group ( p < 0.05) and made it nonsignificant in the LT 4 -Low group. Conclusions: HT pathology increases the risk for DTC only in euthyroid subjects and those with partially functional thyroid glands (LT 4 -Low) but not in fully hypothyroid HT (LT 4 -Mid and LT 4 -High). High TPO-Ab titers appear to protect against DTC in patients with HT.

show abstract

Section: Discussionmentioning

confidence: 99%

Hashimoto's Thyroiditis Pathology and Risk for Thyroid Cancer

Paparodis

Imam

Todorova‐Koteva

et al. 2014

Thyroid

Self Cite

View full text Add to dashboard Cite

show abstract

“…This double negative lymphocyte population was identified as the dominant cell type in PTC and was more abundant in PTC than in thyroid autoimmunity. 106 These cells ex vivo released IFNg and IL-17, thus resembling effector cells.…”

Section: Natural Killer T Cells (Nkt) Gd T Cells and Innate Lymphoidmentioning

confidence: 98%

The immune network in thyroid cancer

2016

View full text Add to dashboard Cite

The immune system plays critical roles in tumor prevention, but also in its initiation and progression. Tumors are subjected to immunosurveillance, but cancer cells generate an immunosuppressive microenvironment that favors their escape from immune-mediated elimination. During chronic inflammation, immune cells can contribute to the formation and progression of tumors by producing mitogenic, prosurvival, proangiogenic and lymphangiogenic factors. Thyroid cancer is the most frequent type of endocrine neoplasia and is the most rapidly increasing cancer in the US. In this review, we discuss recent findings on how different immune cells and mediators can contribute to thyroid cancer development and progression.

show abstract

“…Based on investigation of frozen tissue sections and flow cytometry (Imam et al 2014), they showed that CD3+, CD4− and CD8− lymphocytes were significantly more abundant in PTC (>20%) compared with autoimmune thyroiditis (<5%). Moreover, after PMA/Ionomycin stimulation, the population of CD3+, CD4− and CD8− lymphocytes derived from PTC patients remained unchanged, but increased in samples derived from thyroid autoimmunity patients.…”

Section: :10mentioning

confidence: 99%

Perspectives for immunotherapy in endocrine cancer

Latteyer¹,

Tiedje²,

Schilling³

et al. 2016

Endocrine-Related Cancer

View full text Add to dashboard Cite

The fight against cancer has seen major breakthroughs in recent years. More than a decade ago, tyrosine kinase inhibitors targeting constitutively activated signaling cascades within the tumor inaugurated a new era of oncological therapy. Recently, immunotherapy with immune checkpoint inhibitors has started to revolutionize the treatment of several malignancies, most notably malignant melanoma, leading to the renaissance and the long-awaited breakthrough of immunooncology. This review provides an overview of the basis of immunotherapy from its initial concepts of antitumor immunity and cell-based therapy to the development of immune checkpoint inhibitors and discusses published studies and the perspectives of immunooncology for the treatment of endocrine malignancies.

show abstract

Lymphocytic profiling in thyroid cancer provides clues for failure of tumor immunity

Cited by 43 publications

References 35 publications

Hashimoto's Thyroiditis Pathology and Risk for Thyroid Cancer

Hashimoto's Thyroiditis Pathology and Risk for Thyroid Cancer

The immune network in thyroid cancer

Perspectives for immunotherapy in endocrine cancer

Contact Info

Product

Resources

About